Inhibitory effects of budesonide, desloratadine and dexamethasone on cytokine release from human mast cell line (HMC-1)

Inflamm Res. 2004 Dec;53(12):664-9. doi: 10.1007/s00011-004-1309-6.


Objective: To determine the inhibitory potency of budesonide on interleukin (IL)-4, 6 and 8, GM-CSF and TNF-alpha release from the human mast cell line (HMC-1) in comparison with the systemic glucocorticosteroid, dexamethasone, and H(1) antagonist, desloratadine.

Methods: HMC-1 was stimulated with 25 ng/ml phorbol 12- myristate 13-acetate (PMA) and 2.5 x 10(-7) M ionomycin (A23187) for 6, 12 and 24 h in both the presence and absence of 10(-6)-10(-10) M concentrations of the test drugs. Culture supernatants were collected and assayed by ELISAs.

Results: HMC-1 produced substantial amounts of GM-CSF and IL-8 and smaller amounts of TNF-alpha, IL-4 and IL-6 after being stimulated with PMA together with A23187. Budesonide and dexamethasone had potent inhibitory effects and desloratadine had modest inhibitory effects on the release of these cytokines. Budesonide was more potent than dexamethasone at most concentrations and time points. IL-4 was the cytokine which was most susceptible to inhibition by the three tested drugs. The inhibitory effects, in some cases, were time- and concentration-dependent.

Conclusion: Budesonide had a potent inhibitory effect on cytokine release from HMC-1. Its potency was greater than that of both dexamethasone and desloratadine.

MeSH terms

  • Budesonide / pharmacology*
  • Cell Line
  • Cytokines / metabolism*
  • Dexamethasone / pharmacology*
  • Humans
  • Loratadine / analogs & derivatives*
  • Loratadine / pharmacology*
  • Mast Cells / drug effects*
  • Mast Cells / metabolism*
  • Tetradecanoylphorbol Acetate / analogs & derivatives*
  • Tetradecanoylphorbol Acetate / pharmacology


  • Cytokines
  • Budesonide
  • phorbolol myristate acetate
  • Loratadine
  • Dexamethasone
  • desloratadine
  • Tetradecanoylphorbol Acetate